Flurazepam

Evidence Level: N/A Predicted Indications: 0

Table of Contents

  1. Flurazepam
    1. Pharmacist Assessment Report
    2. Flurazepam: Known uses and market status in India
    3. Summary
    4. Quick overview
    5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
    6. India Market Information
    7. Safety Considerations
    8. Disclaimer

Pharmacist Assessment Report

Flurazepam: Known uses and market status in India

Summary

The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Flurazepam, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. This page lists the known uses and the market status in India.

Quick overview

Item Content
New predicted indications None (all traceable model candidates are known uses)
Known uses among model candidates 0
Evidence level Not applicable
India Market Status Listed in a compiled Indian medicine price dataset (6 of 6) – CDSCO approval status is not included in this data
Number of Listed Products 6 (valid: 6)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication Source
none none
Indication Approved category
none none

Relations recorded in the knowledge graph (no approval found)

Indication
none

India Market Information

Licence Product Dosage form Status
249274 Zomnia 10mg Tablet strip of 10 tablets Valid
155758 Nindral 5mg Tablet strip of 10 tablets Valid
154572 Nindral 15mg Capsule strip of 10 capsules Valid
249371 Zomnia 5mg Tablet strip of 10 tablets Valid
85839 Fluraz 15mg Capsule strip of 10 capsules Valid
153511 Nindral 10mg Tablet strip of 10 tablets Valid

Safety Considerations

  • Contraindications suggested by the knowledge graph (these come from drug-disease relationships, not label text): anxiety and neurotic disorders, dysthymic disorder, porphyria, kidney disease, liver disease, gallbladder disease, psychotic disorders, obstructive sleep apnoea and other sleep apnoea syndromes, respiratory failure, lung disease, substance-related disorders and dependence, personality disorder, intermittent explosive disorder.
  • Drug Interactions: 116 interactions were identified. Major ones include:
    • Morphine
    • Liposomal morphine

    Moderate ones include:

    • Bupropion
    • Omeprazole
    • Cimetidine
    • Clarithromycin
    • Dronabinol
    • Nabilone
    • Metoclopramide
    • Opium
    • Sibutramine
    • Teduglutide
  • Class-related concerns in the literature: residual effects on driving, rebound insomnia on discontinuation, and use in older adults.

Please also refer to the package insert for full safety information.


Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.



This site uses Just the Docs, a documentation theme for Jekyll.